Illumina Appoints Matthew Posard to Lead Worldwide Marketing
News Feb 01, 2006
Illumina, Inc. has announced the appointment of Matthew L. Posard as Vice President of Marketing. Mr. Posard will be responsible for all worldwide strategic and tactical marketing for Illumina.
Mr. Posard has thirteen years of marketing, sales and service experience in the healthcare field, with particular expertise in the diagnostics industry. Most recently, he spent over six years in various sales and marketing director positions at Biosite Inc.
While at Biosite, Mr. Posard oversaw the commercialization of several novel products including the BNP (B-type natriuretic peptide) heart failure diagnostic test now used in over 50% of U.S. hospitals.
Prior to Biosite, Posard held various marketing positions at Gen-Probe, Inc. managing strategic marketing, new product planning, market research, project management, customer service and sales administration.
Posard received his B.A. degree in quantitative economics and decision science from the University of California, San Diego.
"Matt brings great commercialization experience and strong management skills to Illumina," said Jay Flatley, Illumina President and CEO.
"He has a proven ability to operate in regulated environments that we're targeting downstream of the research field, and we're very excited to have him join our senior leadership team."
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.